Catalytic Cleavage of Disulfide Bonds in Small Molecules and Linkers of Antibody-Drug Conjugates

被引:32
|
作者
Zhang, Donglu [1 ]
Fourie-O'Donohue, Aimee [2 ]
Dragovich, Peter S. [3 ]
Pillow, Thomas H. [3 ]
Sadowsky, Jack D. [4 ]
Kozak, Katherine R. [2 ]
Cass, Robert T. [1 ]
Liu, Liling [1 ]
Deng, Yuzhong [1 ]
Liu, Yichin [2 ]
Hop, Cornelis E. C. A. [1 ]
Khojasteh, S. Cyrus [1 ]
机构
[1] Genentech Inc, Drug Metab & Pharmacokinet, 1 DNA Way MS 412a, San Francisco, CA 94080 USA
[2] Genentech Inc, Biochem & Cellular Pharmacol, San Francisco, CA 94080 USA
[3] Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA
[4] Genentech Inc, Prot Chem, San Francisco, CA 94080 USA
关键词
SITE-SPECIFIC CONJUGATION; ANTICANCER PRODRUGS; THIOREDOXIN; CYSTEINE; GLUTATHIONE; DELIVERY;
D O I
10.1124/dmd.118.086132
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In cells, catalytic disulfide cleavage is an essential mechanism in protein folding and synthesis. However, detailed enzymatic catalytic mechanism relating cleavage of disulfide bonds in xenobiotics is not well understood. This study reports an enzymatic mechanism of cleavage of disulfide bonds in xenobiotic small molecules and antibody conjugate (ADC) linkers. The chemically stable disulfide bonds in substituted disulfide-containing pyrrolobenzodiazepine (PBD, pyrrolo[2,1-c][1,4]benzodiazepine) monomer prodrugs in presence of glutathione or cysteine were found to be unstable in incubations in whole blood of humans and rats. It was shown the enzymes involved were thioredoxin (TRX) and glutaredoxin (GRX). For a diverse set of drug-linker conjugates, we determined that TRX in the presence of TRX-reductase and NADPH generated the cleaved products that are consistent with catalytic disulfide cleavage and linker immolation. GRX was less rigorously studied; in the set of compounds studied, its role in the catalytic cleavage was also confirmed. Collectively, these in vitro experiments demonstrate that TRX as well as GRX can catalyze the cleavage of disulfide bonds in both small molecules and linkers of ADCs.
引用
收藏
页码:1156 / 1163
页数:8
相关论文
共 50 条
  • [31] Hydrophilic Sequence-Defined Cross-Linkers for Antibody-Drug Conjugates
    Walker, Joshua A.
    Sorkin, Michelle R.
    Ledesma, Francis
    Kabaria, Sneha R.
    Barfield, Robyn M.
    Rabuka, David
    Alabi, Christopher A.
    BIOCONJUGATE CHEMISTRY, 2019, 30 (11) : 2982 - 2988
  • [32] Monoclonal antibody-drug conjugates
    Hamann, PR
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (09) : 1087 - 1103
  • [33] Enthusiasm for Antibody-Drug Conjugates
    Tuma, Rabiya S.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (20) : 1493 - 1494
  • [34] BUILDING ANTIBODY-DRUG CONJUGATES
    Thayer, Ann M.
    CHEMICAL & ENGINEERING NEWS, 2014, 92 (03) : 13 - +
  • [35] Antibody-Drug Conjugates for Immunology
    Dragovich, Peter S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (06) : 4496 - 4499
  • [36] RETHINKING ANTIBODY-DRUG CONJUGATES
    Jarvis, Lisa M.
    CHEMICAL & ENGINEERING NEWS, 2012, 90 (25) : 12 - +
  • [37] Introduction to Antibody-Drug Conjugates
    Pettinato, Mark C.
    ANTIBODIES, 2021, 10 (04)
  • [38] The Promise of Antibody-Drug Conjugates
    Teicher, Beverly A.
    Doroshow, James H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1847 - 1848
  • [39] Antibody-drug conjugates for cancer
    Chau, Cindy H.
    Steeg, Patricia S.
    Figg, William D.
    LANCET, 2019, 394 (10200): : 793 - 804
  • [40] Payloads for Antibody-Drug Conjugates
    Goundry, William R. F.
    Parker, Jeremy S.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2022, 26 (08) : 2121 - 2123